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Lipoaspirate, a wasted by product from liposuction procedure recently has been shown 
to contain abundant adipose-derived-mesenchymal stem cells (MSCs). Mesenchymal stem cells 
(MSCs) have been studied in many research areas to regenerate many cell lineages. In addition, 
MSCs have immunomodulatory effect. This capability has been utilized in several clinical studies 
in hematopoetic stem cell and organ transplantation as a strategy to reduce the risk of Graft 
versus Host Disease (GvHD). It has been reported that the ‘stimulated’ MSC is able to secrete 
substances to suppress tissue rejection. One of the substances was known to be indoleamine 
2,3-dioxygenase (IDO).  A previous study has characterized the secretion of IDO by bone 
marrow-derived MSCs stimulated by an inflammatory mediator interferon gamma (IFN-γ). IDO 
has been detected using Western blot analysis and by High Performance Liquid 
Chromatography (HPLC) assay. The aim of this study was to detect the presence of IDO in 
AD-MSCs culture with and without INFγ stimulation. Our study showed that AD-MSC 
stimulated with IFN-γ significantly secreted high level of IDO as detected by Enzyme-Linked 
Immuno Sorbent Assay (ELISA). Despite its property as a proinflammatory mediator, IFN-γ has 
shown to be able to induce IDO secretion in MSC culture which suggests the immuno 
modulatory effect of MSC. This study clearly demonstrates the potential application of adipose-
derived MSC in the immunomodulatory strategy for allogenic transplantation.   
 




Mesenchymal stem cells (MSCs) comprise 
a population of multipotent progenitor cells 
capable of both supporting hematopoiesis as well 
as to differentiate into many tissue lineages.  In the 
appropriate microenvironment, MSCs differentiate 
into various cell types, including cells originated 
from mesodermal lineage (adipocytes, osteoblasts, 
chondrocytes, and cardiomyocytes), into 
endoderm-derived cells (hepatocytes) and 
ectoderm-derived cells (neurons)(Sanchez-Ramos 
et al., 2000; Schwartz et al., 2002; Zhang et al., 
2008). Recently utilization of MSCs have been 
reported to prevent severe graft-versus-host 
disease (GvHD) in allogenic transplantation (Le 
Blanc et al., 2004). Mesenchymal stem cells have 
low immunogenicity and are capable of inhibiting 
allogenic T-cell responses(Le Blanc, 2006). MSCs 
may evade the detection and elimination by the 
immune system, and suppress alloreactivity 
through modulation of most major immune cell 
activities. However, the exact mechanism of the 
immunomodulatory effects of MSCs is not 
completely understood. Both direct and indirect 
effects have been suggested through either cell-cell 
interaction or soluble factors that create a local 
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Several compounds such as hepatocyte 
growth factor (HGF), transforming growth factor 
(TGF-β1) (Di Nicola et al., 2002), IL-10, IL6, 
prostaglandin E2 (Aggarwal and Pittenger, 2005), 
nitric oxide (Sato et al., 2007) and indoleamine 
2,3-dioxygenase (IDO) (Meisel et al., 2004) 
secreted by MSCs have been reported to involve in 
MSCs  immunomodulatory effect . 
There are several sources of MSCs i.e.  
bone marrow, umbilical cord blood, peripheral 
blood and adipose tissue. Human Adipose 
Derived-stem cells (hADSCs) share unique 
features of its counterpart in bone marrow, such as 
differentiation potential, low immunogenicity and 
the ability to suppress immune response (Puissant 
et al., 2005; Yanez et al., 2006)  
IDO is an apoenzyme that is encoded by a single 
gene with 10 exons in human chromosome 8 
(Suzuki et al., 2003). Various cell types, including 
certain myeloid-lineage cells (monocyte-derived 
macrophages and dendritic cells), fibroblasts, 
endothelial cells and some tumour-cell lines, 
express IDO after exposure to IFN-γ. (REFF) IDO 
activity is found constutively at maternal-fetal 
interface, and is expressed by human extravillous 
trophoblast cells. Outside placenta, functional IDO 
expression was reported to be highest in the mouse 
epididymis, gut, lymph nodes, spleen thymus and 
lungs (Mellor and Munn, 2004). The presence of 
constitutive and inducible IDO expression in these 
tissues might function as an anti-
inflammatory/immunosuppressive mechanism, 
(Mellor 2004) by initiating the degradation of 
tryptophan along the kynurenine pathway. Some of  
tryptophan metabolites suppress T cell 
proliferation in vitro or cause T cell apoptosis and 
some can affect NK cell function (Munn and 
Mellor, 2007). 
A previous study has characterized the 
secretion of IDO by bone marrow-derived MSCs 
stimulated by an inflammatory mediator interferon 
gamma (IFNγ). (REFF) IDO has been detected 
using Western blot analysis and High Performance 
Liquid Chromatography (HPLC) assay. The aim of 
this study was to detect the presence of IDO in 
AD-MSCs culture with and without INF-γ 
stimulation by Enzyme-Linked Immuno Sorbent 




Mesenchymal stem cell isolation from 
lipoaspirates 
Protocols in this study have been reviewed 
and approved by the Stem Cell and Cancer 
Institute Institutional Review Board prior to the 
study (number 13/IRB/SCI/KF/2008 and 
19/IRB/SCI/KF/2010). Lipoaspirates, which were 
discarded waste materials from individuals who 
experienced tumescent liposuction surgery were 
obtained from hospitals in Jakarta. Lipoaspirates 
were stored at 2–8°C for no longer than 24 hours 
before they were used. The methods used to isolate 
the MSCs from lipoaspirate were adapted from 
previously reported (Sardjono et al., 2009; Suzuki 
et al., 2001) The raw lipoaspirates  were washed 3 
times by diluting them with equal volume of 
Phosphate Buffer Saline (PBS). The diluted 
lipoaspirates were centrifuged at 430×g for 10 
minutes without brakes at 20
o
C. After 
centrifugation, the target cell–containing lipid 
phase was removed from the top and transferred in 
to new tubes and diluted with an equal volume of 
PBS.  The next step was digesting the cell-
containing lipid fraction with an equal volume of 
pre-warmed (37
o
C) 0.075% collagenase type I 
(Sigma) in PBS. Enzyme digestion was done by 
incubation at 37 °C for 30 minutes on an orbital 
shaker. After digestion, enzyme activity was 
neutralized by adding an equal volume of 
Dulbecco’s modified Eagle’s medium (DMEM) 
containing 10% Fetal Bovine Serum (FBS). 
Digested product was then subjected to 
centrifugation at 600×g for 10 minutes. The pellet 
was resuspended in DMEM with 10% PBS, and 
then filtered through a 100-µm strainer mesh. The 
collected cells after filtration were then ready for 
utilization. An aliquot was taken for cell count 
using hemocytometer under a light microscope to 
determine cell yields. Viable cell count was 
determined with a hemocytometer and the trypan 
blue dye exclusion technique.  
 
MSCs culture  
The simplest technique to purify MSC from 
other contaminating cells was done by allowing 
the cells to adhere on plastic-surfaced disc. Cells 




 in MesenCult 
complete medium (StemCell Technologies 05401 
and 05402), 100 unit/ml penicillin and 0.1 mg/ml 
streptomycin (Sigma P0781), then kept in 37
o
C, 
5% CO2. After 2-3 days unwanted cells (non-
MSCs and debris) were removed by two washes 
with medium, and MSCs were expanded to reach 
80% confluence. In subsequent 6-7 days, adherent 
cells were detached using 0.25% trypsin EDTA 
solution (Sigma T4049), then DMEM medium + 
20% FBS was used to inactivate the trypsin. 
Detached cells with fibroblast-like morphology 





 for 1 week or until confluence 
was achieved. For IFN-γ stimulation, cells were 
Laksmitawati, et al., 2010 




seeded at 5000 cells/cm2 in Mesencult medium 
and were incubated until the cells were attached (1 
hour). Interferon γ was added to the culture.  We 
use IFN-γ 10, 50, 100 and 200 IU/ml medium. The 
supernatants were collected in the sixth day of 
culture and kept in -80
o
C after sentrifugation to 
separate the floating dead cells. 
 
Flowcytometry assay to determine MSC 
homogenous population  
To confirm the quality of the MSCs 
isolated, several assays were conducted. We use 
positive (CD105, CD73) and negative MSCs 
markers (HLA-DR, CD 14, CD 19, CD 45 and CD 
34).  Cells were harvested and stained with the 
appropriate surface monoclonal antibodies (PE 
conjugated: CD105 (abcam 53321-100), CD73 
(BD550257), HLA-DR (abcam 23901), CD 19 
(abcam 1168-500); FITC-conjugated CD14 
(abcam 28061-100), CD45 (BD 555482) and CD 
34 (BD 348053)) following manufacturer’s 
instructions. Isototype controls (mIgG1 
(BD349041 and BD 349043), and mIgG2 
(BD349053)) were used to determine background 
staining. After washing, the cells were fixed, and 
5000 events were acquired using a FACS Calibur 3 
argon laser 488nm (Becton Dickinson). Cell-
Quest-pro software was used for acquisition and 
analysis.  
 
ELISA methods to measure IDO 
IDO was measured with ELISA kit 
(E1547Hu, Uscn Life Science Inc.Wuhan). The 
microtiter plate was pre-coated with an antibody 
specific to IDO. Standards (0–100 IU/mL) or 
samples were then added to the appropriate 
microtiter plate wells followed by a biotin-
conjugated polyclonal antibody specific for IDO. 
Next avidin conjugated to Horseradish Peroxidase 
(HRP) was added to each microplate well and 
incubated for 30 minutes. A tetramethylbenzidin 
(TMB) substrate solution was added to each well. 
The presence of IDO in the samples was detected 
by biotin-conjugated antibody and enzyme-
conjugated avidin, the enzyme-substrate reaction 
was terminated by addition of a sulphuric acid 
solution and the color change was measured 
spectrophotometrically at wavelength of 450 nm. 
Standard curve with known IDO concentration was 
generated using 100, 50, 25, 12.5, 6.25, 3.12, 1.56, 
0 (blank) IU/mL. The concentrations of IDO in the 
samples were determined by projecting the 





Morphology and surface markers of 
mesenchymal stem cells  
Using the described methods, MSCs were 
able to be obtained from lipoaspirate. In cell 
culture, the isolated cells showed a fibroblast-like 
morphology, which is characteristic for MSCs 
(Figure 1). Contaminant cells could be eliminated 
by passaging cells. High purity MSCs could be 
achieved after the second passage. To confirm the 
purity of MSCs we used some of the suggested 
markers according to ISCT (Dominici et al., 2006) 
and measured the purity by flow cytometer. 
 Cell surface molecules expressions were 
determined by flowcytometry assay. Based on 
standard criteria for defining multipotent 
mesenchymal stem cells, we characterized the 
cultured cells using markers for CD105 (known as 
endoglin), and CD73 (ecto 5’-nucleotidasethat is 
recognized by SH3 and SH4). We confirmed our 
isolated and cultured cells were MSCs as they 
mainly expressed CD105 and CD 73, but did not 
HLA-Class II, CD 45, CD 34, CD14, and CD19 
(Figure 2), which was consistent with the profile 
of MSCs. In this study, the flowcytometry gated 
results for CD 105, CD 73, CD34, CD 45, were 
92.04%, 99.68%, 0.07, 0.22%  respectively and  
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Figure 1. ADSCs showed fibroblast-like morphology 
                  
 
 
Figure 2.  Flowcytometry analysis of molecules expression on MSC from lipoaspirate. Flowcytometry assay 
showed the cultured cells were consistent with the characteristic of MSC, i.e. CD 105 and CD73 
were positive, while CD- 45, CD34, CD19 , CD14 and HLA-DR were negative (< 1%). 
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Figure 3. IDO level (IU/mL) in ADSC culture with passage varian. Using lipoaspirate from 2 different 
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Figure 4.  Secreted IDO in the culture with and without IFN-γ stimulation by ELISA. 
 IDO level in AD-MSCs        
In this study, AD-MSCs samples from 2 
donors and different passages showed about the 
same IDO level. The level range was 42.86–52.82 
IU/mL (Figure 3) The quantity of secreted IDO 
was higher when the culture was stimulated with 
IFN-γ (81,25-94,79 IU/mL) (Figure 4). The 
secreted IDO level showed a positive association 
trend with the increasing IFN-γ level by culturing 




MSC can be isolated from adipose tissue. 
Here we isolated MSC from liposuction, which 
was a waste from surgery. With a modified simple 
protocol adopted from Zuk et al. (2009) and 
Sardjono et al. (2009) we could get MSCs. The 
purity of MSC devoid of hematopoietic cells could 
be achieve after passage 2. This cells might be an 
alternative source of MSCs beside bone marrow-
derived cells. 
The use of MSCs in regenerative medicine 
is of great interest and represents a major goal to 
achieve in the coming years. The interest resides in 
their ability to be easily isolated and expanded ex 
vivo and multipotential differentiation capabilities 
together with their immunosuppressive properties. 
Soluble factors such HGF, PGE2), TGF-β1, IDO, 
nitric oxide and IL-10 have been implicated. 
Several reports have also shown that inflammatory 
cytokines such as TNF-α and IFN-γ may regulate 
the MSC mediated immunosuppresion (DelaRosa 
et al., 2009).  Several studies have measured IDO 
in MSC culture. By different method in this study, 
we analyzed IDO level by ELISA method in 
ADSC culture stimulated with and without IFN-γ. 
This study showed that IDO was secreted to 
the supernatant of ADSC culture with or without 
IFN-γ stimulation. The quantity of secreted IDO in 
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culture with IFN-γ was higher compared to culture 
without IFN-γ addition.  Several studies showed 
that IFN-γ was a prerequisite for IDO secretion. 
The difference found in our result might be due to 
the fact that we did not measure IDO level in the 
medium. As we used ELISA kit to detect IDO, the 
antibody might react with IDO-like proteins in the 
medium. Therefore IDO level in unstimulated 
culture can be regarded as baseline. 
DelaRosa et al, 2009 measured IDO activity 
by determining both Trp and Kyn level in 
conditioned supernatant from ADSC culture using 
HPLC They found that IDO activity was induced 
by IFN-γ stimulation. Further, IDO activity was 
significantly reduced when IFN-γ signaling was 
blocked with anti bodies. A study on IDO gene 
inserted hADSC clone showed that hADSC-IDO 
cells secreted the active enzyme constutively, 
which resulted in increased Kyn level in the 
medium. The IDO activity was further increased 
by IFN-γ stimulation. The hADSC without 
inserted IDO gene did not show an increase in Kyn 
level in the medium after 48 hours of 
culture.(DelaRosa et al., 2009) 
Meisel et al, (2004), detected the secretion 
of IDO by Western blot method, and measured the 
IDO activity by photometric determination of 
kynurenin concentration in the supernatant. After 3 
days, bone marrow stem cells (BMSCs) with and 
without IFN- γ stimulation  were harvested and 
subjected to Western blot analysis using IDO-
specific monoclonal antibody. Human BMSC 
secreted IDO only upon stimulation with IFN-γ at 
a concentration of 500 U/mL. They showed that 
hBMSCs expressed functional IDO activity upon 
stimulation with IFN-γ. The higher the 
concentration of IFN-γ the greater the IDO activity 
(Meisel et al., 2004)  
This result is in line with our data. Our 
data showed positive association trend of between 
IFN-γ and IDO level that was measured by ELISA. 
Our data showed that IDO could be detected in 
ADSC culture without addition of IFN-γ. However 
IFN-γ addition caused e higher IDO secretion. This 
result differed from the result of a recent study. 
There are many factors that may cause the 
difference between our result and the recent study, 
such as the methods of IDO detection, period of 
culturing, source of MSC, media and the 
concentration of IFN-γ for the stimulation. 
  Interferon gamma is a proinflammatory 
mediator, but in MSC culture, it behaves 
differently, because INFγ stimulates IDO secretion 
that has an immunomodulatory effect. This study 
clearly demonstrates the potential application of 
AD-MSC in the immunomodulatory strategy for 




By detecting IDO with ELISA method in 
the supernatant of a 6 day AD-MSCs culture, we 
found that IDO could be secreted. Addition of 
IFN-γ resulted in higher secretion of IDO. 
This study clearly demonstrates the potential 
application of AD-MSCs in the 
immunomodulatory strategy for allogenic 
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